INFECTIOUS DISEASE AEROBIOLOGY CORE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 传染病空气生物学核心现已在TNRPC全面运作。 该核心具有生物气溶胶表征和各种传染性病原体的气溶胶挑战所需的所有技术能力;该核心还能够进行疫苗和治疗剂的气溶胶递送。 接触设施位于疾病控制和预防中心批准的特选制剂注册生物安全3级（BSL-3）设施内，该设施位于TNPRC。 在一个新的更大的BSL-3设施中建造了第二个暴露设施，一旦投入使用和检查，将成为堆芯的主要位置。 除了非人类灵长类动物气溶胶暴露能力外，该核心还对较小动物进行气溶胶暴露。 这个核心的建立提供了一个独特的资源，使研究人员能够进行关键实验，以进一步了解空气传播的传染病的生物学基础。 除了核心主任Chad J. Roy博士外，核心还配备了全职研究科学家Satheesh Sivasubrahamni博士。 核心的微生物支持还包括Deepak Kaushal博士的支持。 在运行的最后一年，核心一直从事合作研究与内部和NIH资助的校外研究人员;核心的校外用户的数量超过10个合作实验室。 大多数核心合作研究涉及实验性气溶胶感染，作为更广泛研究目标（如疾病模型开发或疫苗有效性）的重要组成部分。 除了实验性感染外，该核心还有助于为新型病原体（例如，RSV）和气溶胶活力评估。 要求使用新型微生物剂进行微生物效率研究（例如，裸DNA、伯克霍尔德氏菌属（Burkholderia sp.）随着合作实验室了解到通过该核心提供的能力，

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The infectious disease aerobiology core is now fully operational at the TNRPC. The core has all the technical capabilities required for bioaerosol characterization and aerosol challenge of diverse infectious agents; the core is also capable of aerosol delivery of vaccines and therapeutics. The exposure facility is located within the CDC-approved select agent registered biosafety level 3 (BSL-3) facility located at the TNPRC. A second exposure facility has been constructed in a new larger BSL-3 facility and, once commissioned and inspected, will become the primary location for the core. In addition to nonhuman primate aerosol exposure capability, the core also performs aerosol exposures on smaller animals. Establishment of this core provides a unique resource that enables investigators to perform key experiments to further understand the biological basis of airborne-transmitted infectious diseases. In addition to the core director Dr. Chad J. Roy, the core is staffed by Dr. Satheesh Sivasubrahamni who serves as a fulltime research scientist. Microbiological support for the core also includes support from Dr. Deepak Kaushal. In the last year of operation, the core has been consistently engaged in collaborative research studies with both intramural and NIH-funded extramural investigators; the number of extramural users of the core exceeds ten collaborating laboratories. The majority of core collaborative research involves experimental aerosol infection as an essential component of studies broader research goals such as disease model development or vaccine efficacy. In addition to experimental infection, the core is instrumental in providing aerosol characterization for novel pathogenic agents (e.g., RSV) and aerosol viability assessment for viral-vectored vaccine products. Requests for microbial efficiency studies using novel microbial agents (e.g., naked DNA, Burkholderia sp.) have also continued to increase as collaborative laboratories learn of the capabilities made available through this core.